Charm Therapeutics Ltd. has closed an oversubscribed series B funding round, raising $80 million to advance its next-generation menin inhibitor into clinical development. Current menin inhibitors show promise in acute myeloid leukemia (AML) treatment but are limited by the rapid emergence of resistance mutations that cause treatment failure.
Glioblastoma (GBM) is the most common and malignant primary brain tumor. Non-muscle myosin II (NMII) paralogues (NMIIA, IIB and IIC) have multiple roles in normal cell physiology, but also contribute to pathological states, including GBM. Because oncogenic kinase inhibitors often fail in GBM due to pathway redundancy, targeting NMIIs, which are common downstream effectors, may offer a more effective strategy.
“The impoverished laboratory environment in which mice and rats are maintained has been very good at increasing experimental replicability,” Steven Austad told the audience at the 12th Aging Research & Drug Discovery Meeting (ARDD) in Copenhagen last week. “But at the cost of sacrificing translational relevance.”
Mitochondrial transfer is known to occur from the tumor microenvironment into cancer cells, but now, Swiss researchers have shown a possible precursor to this is that cancer cells smuggle their mitochondria into healthy connective tissue cells, prompting their reprogramming to cancer-associated fibroblasts.
Scientists at Emory University and Hadasit Medical Research Services and Development Ltd. have described nuclear receptor ROR-α agonists reported to be useful for the treatment of liver cancer, pancreatitis, diabetes, obesity, immunological disorders, neurological disorders, liver diseases and metabolic diseases, among others.
Beijing Sciwind Biotechnology Co. Ltd. and Sciwind Biosciences Co. Ltd. have divulged glucagon-like peptide 2 receptor (GLP-2R) agonists reported to be useful for the treatment of Crohn’s disease, irritable bowel syndrome, malnutrition, ulcerative colitis, obesity and graft-vs.-host disease.
Shanghai Helioson Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase-binding moiety covalently bonded to a Bruton tyrosine kinase (BTK)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer and autoimmune diseases.
Samjin Pharmaceutical Co. Ltd. has synthesized Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, inflammatory bowel disease, arthritis and migraine.
Intelligen Therapeutics Co. Ltd. and Intelligen Therapeutics Inc. have disclosed macrocyclic compounds acting as TNF-α inhibitors reported to be useful for the treatment of inflammation and autoimmune diseases.
The TCF4/β-catenin axis is a key driver of tumor growth, where β-catenin has remained resistant to therapy and is traditionally considered an undruggable protein. At the ACS Fall 2025 meeting, Parabilis Medicines Inc. divulged results of work on hyperstabilized α-helical peptides named helicons that directly bind to β-catenin and block its interaction with TCF transcription factors such as TCF4, as well as inhibit the Wnt signaling pathway.
RSS
